Ignite Creation Date:
2024-05-06 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 2:22 PM
Study NCT ID:
NCT05200481
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-07
First Post:
2022-01-07
Brief Title:
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer MASTERPROTOCOL ALK
Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Organization:
Intergroupe Francophone de Cancerologie Thoracique
Organization Data
Organization:
Intergroupe Francophone de Cancerologie Thoracique
Class:
OTHER
Study ID:
IFCT-2101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None